[Hinews] SEOUL, South Korea — A research team led by Professors Byung-Chul Cho and Ki-Bbeum Lee, alongside resident physician Ju-Seong Sim at Yonsei Cancer Center, has unveiled new possibilities for MET gene targeted therapy in treating solid tumors, according to a study published on July 30 in Nature Reviews Clinical Oncology, a leading journal in the field of oncology.

The MET gene, known for its role in cancer cell growth and metastasis, has long been a focal point in non-small cell lung cancer (NSCLC) treatment. Overexpression of MET in NSCLC has been linked to significant anti-cancer effects when targeted, and such therapies are already in clinical use. Now, the Yonsei team suggests this approach could extend to other solid tumors, including colorectal and gastric cancers.

From left, Professors Byung-Chul Cho and Ki-Bbeum Lee of Yonsei Cancer Center’s Department of Medical Oncology, alongside resident physician Ju-Seong Sim. (Photo courtesy of Severance Hospital
From left, Professors Byung-Chul Cho and Ki-Bbeum Lee of Yonsei Cancer Center’s Department of Medical Oncology, alongside resident physician Ju-Seong Sim. (Photo courtesy of Severance Hospital


The researchers found that MET gene aberrations are present across various cancer types, and early diagnosis paired with targeted therapy could enhance treatment outcomes. The study also highlights ongoing research into combination therapies, integrating MET inhibitors with immune checkpoint inhibitors and antibody-drug conjugates (ADCs).
A key finding centers on MET-targeted therapy as a novel option for patients who develop resistance to EGFR inhibitors. When resistance to EGFR inhibitors emerges, MET gene overexpression often compensates, driving tumor growth. By simultaneously targeting MET, the researchers propose, anti-cancer efficacy can be sustained.

“Our findings confirm that the MET gene is a significant therapeutic target not only in lung cancer but also in colorectal, gastric, and other solid tumors,” said Professor Byung-Chul Cho. “This approach offers a promising new strategy for patients with EGFR inhibitor resistance.”

The study underscores the growing potential of precision oncology, where therapies are tailored to specific genetic alterations, offering hope for improved outcomes across a broader spectrum of cancers.

키워드

#표적치료#암치료#면역항암제#MET유전자표적치료
저작권자 © Hinews 무단전재 및 재배포 금지
ad